265 related articles for article (PubMed ID: 17785116)
1. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
[TBL] [Abstract][Full Text] [Related]
2. [Changes and significance of peripheral blood count in tumor rejection induced by a low dose of melphalan in C57BL/6 mice].
Shu XH; Li CG; Li ML; Michael N; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jun; 25(6):498-500. PubMed ID: 19500501
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan].
Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):235-8. PubMed ID: 16507262
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between anti-tumor effects of melphalan and IFN-gamma].
Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):594-6. PubMed ID: 16948903
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice].
Li ML; Li CG; Shu XH; Jiang MN; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):320-3. PubMed ID: 17428385
[TBL] [Abstract][Full Text] [Related]
6. [The significance and function of IFN-gamma on the changes of peripheral blood platelet count during tumor-rejection induced by a low dose of melphalan in C57BL/6 mice].
Li CG; Shu XH; Han D; Li ML; Notter M; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Nov; 25(11):1016-9. PubMed ID: 19900371
[TBL] [Abstract][Full Text] [Related]
7. [Study of the immunological mechanism of anti-tumor effects of 5-FU by establishing EL4 tumor-bearing mouse models].
Li ML; Li CG; Shu XH; Li MX; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1010-3. PubMed ID: 17988579
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
9. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.
Roboz J; Jiang J; Holland JF; Bekesi JG
Cancer Res; 1997 Nov; 57(21):4795-802. PubMed ID: 9354441
[TBL] [Abstract][Full Text] [Related]
10. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
11. [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
Hu S; Hu CP; Liang CH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1493-8. PubMed ID: 16061030
[TBL] [Abstract][Full Text] [Related]
12. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ
Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
[TBL] [Abstract][Full Text] [Related]
13. Effects of arsenic trioxide under different administration ways on T-cell lymphoma xenografts in nude mice: in vivo and in vitro experiments.
Gao Y; Cai QQ; Li S; Bu Q; Liao H; Zhou Y; Huang HQ
Ai Zheng; 2009 Feb; 28(2):127-31. PubMed ID: 19550119
[TBL] [Abstract][Full Text] [Related]
14. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
Papadopoulou MV; Ji M; Bloomer WD
In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811
[TBL] [Abstract][Full Text] [Related]
15. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study of interleukin-12 gene vaccines in the treatment of low-load malignant lymphoma (EL4)].
Jiang Q; Da W; Ou Y
Zhonghua Xue Ye Xue Za Zhi; 2001 Nov; 22(11):565-8. PubMed ID: 11855142
[TBL] [Abstract][Full Text] [Related]
17. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effects of matrix protein of vesicular stomatic virus on EL4 lymphoma mice].
Lin SJ; Yu QM; Meng WT; Wen YJ; Chen LJ; Niu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):213-7. PubMed ID: 21500556
[TBL] [Abstract][Full Text] [Related]
19. [Changes and significance of peripheral blood platelet count in tumor shrinkage induced by a low dose of CTX in T739 mice].
Li ML; Jia YJ; Jiang MN; Shu XH; Li CG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun; 24(6):567-9. PubMed ID: 18538085
[TBL] [Abstract][Full Text] [Related]
20. [Relationships between tumor shrinkage and peripheral blood cell changes during tumor-rejection induced by a high dose of 5-FU in C57BL/6 mice].
Li CG; Li ML; Shu XH; Liu YJ; Michael N; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Feb; 24(2):156-8. PubMed ID: 18237534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
